Updated on 21 November 2012
"While CSIR has supported the generic industry in the past with great success and few biotech products have reached market, in this open market era, CSIR is dedicated towards innovation. This includes developing new chemical entities (NCE), establishing novel therapeutic pipelines and setting up biotech start-ups. Open source drug discovery (OSDD) is the new way to energize younger generation to take up drug development and also tackle poor man's diseases through new mechanisms.
- Dr Rajesh Gokhale, director, Institute of Genomics and Integrative Biology (IGIB), New Delhi
"The joint useful and productive partnership between CSIR and the pharmaceutical industry in the post India Patent Act 1970 era has laid foundation on which was built the active pharmaceutical ingredient (API) manufacturing industry as it exists today."
- Dr YK Hamied, chairman, Cipla
"We at Premas, have had a very fruitful and stimulating relationship with open source drug discovery (OSDD) and CSIR. The journey has been educative and interesting."
- Dr Prabuddha Kundu, executive director, Premas Biotech